FindTrial
Sign In

Alternate Day Buprenorphine Administration, Phase X - 15

Alternate Day Buprenorphine Administration, Phase X

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000233
Enrollment
0
Registered
1999-09-21
Start date
1993-05-31
Completion date
Unknown
Last updated
2005-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders

Brief summary

The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.

Interventions

DRUGBuprenorphine

Sponsors

University of Vermont
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
34 Years to 51 Years
Healthy volunteers
No

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frame
Opioid withdrawal—
Subjective dose estimate—
Drug effect characteristics: ARCI—
Money choice—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026